Reactive oxygen species scavenging and inflammation mitigation enabled by biomimetic prussian blue analogues boycott atherosclerosis
Open Access
- 31 May 2021
- journal article
- research article
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 19 (1) , 1-13
Abstract
Background: As one typical cardiovascular disease, atherosclerosis severely endanger people’ life and cause burden to people health and mentality. It has been extensively accepted that oxidative stress and inflammation closely correlate with the evolution of atherosclerotic plaques, and they directly participate in all stages of atherosclerosis. Regarding this, anti-oxidation or anti-inflammation drugs were developed to enable anti-oxidative therapy and anti-inflammation therapy against atherosclerosis. However, current drugs failed to meet clinical demands.Methods: Nanomedicine and nanotechnology hold great potential in addressing the issue. In this report, we engineered a simvastatin (Sim)-loaded theranostic agent based on porous manganese-substituted prussian blue (PMPB) analogues. The biomimetic PMPB carrier could scavenge ROS and mitigate inflammation in vitro and in vivo. Especially after combining with Sim, the composite Sim@PMPB NC was expected to regulate the processes of atherosclerosis. As well, Mn2+release from PMPB was expected to enhance MRI.Results: The composite Sim@PMPB NC performed the best in regulating the hallmarks of atherosclerosis with above twofold decreases, typically such as oxidative stress, macrophage infiltration, plaque density, LDL internalization, fibrous cap thickness and foam cell birth, etc.Moreover, H2O2-induced Mn2+release from PMPB NC in atherosclerotic inflammation could enhance MRI for visualizing plaques. Moreover, Sim@PMPB exhibited high biocompatibility according to references and experimental results.Conclusions: The biomimetic Sim@PMPB theranostic agent successfully stabilized atherosclerotic plaques and alleviated atherosclerosis, and also localized and magnified atherosclerosis, which enabled the monitoring of H2O2-associated atherosclerosis evolution after treatment. As well, Sim@PMPB was biocompatible, thus holding great potential in clinical translation for treating atherosclerosis.GraphicKeywords
Funding Information
- National Natural Science Foundation of China (82022033,, 81771836,, 81725008,, 81927801, 82060311)
- Shanghai Municipal Commission of Health and Family Planning (2018YQ31,, SHSLCZDZK03502,, 2019LJ21)
- Shanghai Rising-Star Program (19QA1406800)
- Shanghai Talent Development Fund (2019040)
This publication has 39 references indexed in Scilit:
- Evolving Concepts of Oxidative Stress and Reactive Oxygen Species in Cardiovascular DiseaseCurrent Atherosclerosis Reports, 2012
- Macrophages in the Pathogenesis of AtherosclerosisCell, 2011
- The immune system in atherosclerosisNature Immunology, 2011
- The immune response in atherosclerosis: a double-edged swordNature Reviews Immunology, 2006
- Inflammation, Atherosclerosis, and Coronary Artery DiseaseNew England Journal of Medicine, 2005
- Inflammation in atherosclerosisNature, 2002
- Inflammation and AtherosclerosisCirculation, 2002
- Magnetic Resonance Imaging of Atherosclerotic Plaque With Ultrasmall Superparamagnetic Particles of Iron Oxide in Hyperlipidemic RabbitsCirculation, 2001
- Atherosclerosis — An Inflammatory DiseaseNew England Journal of Medicine, 1999
- Atherosclerosis: Basic MechanismsCirculation, 1995